Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to improve security and safety of prescription drug supply chains in America.
The problem
Drug supply chains may be vulnerable to counterfeiting, theft, or contamination, potentially putting patients at risk.
The proposal
Establishes requirements to track and verify pharmaceuticals from manufacture through patient delivery using secure systems.
The impact
Affects pharmaceutical manufacturers, pharmacies, healthcare providers, and patients by requiring new tracking and verification procedures.
Better tracking makes it harder for fake medications to enter the supply chain. This protects patients from dangerous counterfeit drugs that don't contain proper medicine.
Secure supply chains mean patients receive authentic medications as prescribed. This reduces risk of serious health problems from contaminated or fake drugs.
Better tracking helps authorities catch drug theft and illegal sales faster. Clearer records make it easier to investigate pharmaceutical crimes.
Monitoring drug safety at every step helps prevent outbreaks of harm. Early detection of contamination can stop problems before they spread widely.
Pharmaceutical companies and pharmacies must invest in new tracking technology and systems. These expenses could raise drug prices for consumers.
Smaller pharmacies and distributors may struggle to adopt expensive new systems quickly. Compliance could be difficult for small healthcare businesses.
Detailed tracking systems collect information about patient medications and prescriptions. This sensitive health data could raise privacy and confidentiality issues.
New verification requirements could slow down pharmacy delivery times. Patients might face longer waits for prescriptions while systems verify drugs.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.